* 泰国富豪谢氏家族旗下制药公司--中国生物制药1177.HK周二早盘低开1.5%后转升最多5.4%，创2024年11月8日以来新高。
* 该公司此前公告称，自主研发的罗伐昔替尼用于治疗慢性移植物抗宿主病（cGVHD）的Ib/IIa期临床研究结果已发表于国际血液学领域顶级期刊《血液》。该研究旨在评价罗伐昔替尼治疗糖皮质激素难治性或依赖性慢性移植物抗宿主病的安全性和有效性。
中国生物制药并指，研究结果显示，罗伐昔替尼在cGVHD人群中展现出优异的临床缓解率、良好的耐受性，同时可以改善糖皮质激素难治性或依赖性cGVHD患者的生活质量，并降低对糖皮质激素剂量的需求。
* 中国生物制药今年迄今涨9.7%，同期恒生指数.HSI大幅上扬17.6%。
* 恒生香港上市生物科技指数.HSHKBIO盘中一度升1.4%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 张喜良)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.